

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	<b>In accordance with the letter dated June 5, 2001</b>
1. CorScan Plus	3. License No. 47-25351-01 <b>is amended in its entirety to read as follows:</b>
2. P.O. Box 789 Lewisburg, West Virginia 24901	4. Expiration Date: June 30, 2011
	5. Docket No. 030-34021

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Iodine 131	C. Any unsealed form for preparation and administration as specified in 10 CFR 35.300 (capsules or liquid unit doses)	C. 55.5 Megabecquerels (1.5 curies)
D. Any byproduct material with a half-life of less than 120 days, except I-131	D. Any unsealed form for preparation and administration as specified in 10 CFR 35.300	D. As needed

9. Authorized Use:

- A. Medical use identified in 10 CFR 35.100.
- B. Medical use identified in 10 CFR 35.200.
- C. and D. Medical uses in 10 CFR 35.300

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License No.  
47-25351-01Docket No.  
030-34021**Amendment No.**  
**15**

## CONDITIONS

10. A. Licensed material may be used at:

CorScan Plus Basement Nuclear Medicine  
Davis Stuart Road  
Lewisburg, WV 24901

- B. Licensed material may be used at:

CorScan Plus  
Out-Patient Clinical Building  
Summersville Hospital  
400 Fairview Heights  
Summersville, WV 26651

- C. Licensed material in 6.A and 6.B may be used at:

CorScan Plus  
Cardiovascular Associates  
681 Hioaks Rd, Suite H  
Richmond, VA 23225

- D. Licensed material in 6.A and 6.B may be used at:

CorScan Plus Imaging  
5875 Bremono Road, Suite 601  
Richmond, Virginia 23226-1928

11. The Radiation Safety Officer for this license is Steven W. Walter, M.D.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.  
47-25351-01

Docket No.  
030-34021

**Amendment No.**  
**15**

12. Licensed material listed in Item 6 above shall be used by, or under the supervision of, the following individuals for the materials and uses indicated:

	<b>Authorized User</b>	<b>Material and Use</b>
A.	Steven B. Hefter, M.D.	Cardiac imaging uses identified in 10 CFR 35.200
B.	Shaival J. Kapadia, M.D.	Cardiac imaging uses identified in 10 CFR 35.200
C.	David C Maki, M.D.	Medical uses identified in 10 CFR 35.100, §35.200 and iodine 131 for the treatment of hyperthyroidism.
D.	Scott Miller, M.D.	Cardiac imaging uses identified in 10 CFR 35.200
E.	Duong Xuan Nguyen, M.D.	Cardiac imaging uses identified in 10 CFR 35.200
F.	Gary Roberts, D.O.	Medical uses identified in 10 CFR 35.100 and §35.200
G.	Colin A. Rose, M.D.	Medical uses identified in 10 CFR 35.100, §35.200 and I-131 for the treatment of hyperthyroidism
H.	Heather Rose, M.D.	Medical uses identified in 10 CFR 35.100, §35.200 and §35.300
I.	Krishnajiuan C. Shah, M.D.	Medical uses identified in 10 CFR 35.100 and §35.200
J.	Jashvantlal Thakker, M.D.	Cardiac imaging uses identified in 10 CFR 35.200
K.	Steven W. Walter, M.D.	Medical uses identified in 10 CFR 35.200
L.	Ansuya A. Amin, M.D.	Medical uses in 10 CFR 35.100 and §35.200
M.	Vipal Sabharwal, M.D.	Cardiac imaging uses identified in 10 CFR 35.200
N.	Massimo Giusti, M.D.	Cardiac imaging uses identified in 10 CFR 35.200

13. Sealed sources containing licensed material shall not be opened by the licensee.

14. In addition to the possession limits in item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35 for establishing decommissioning financial assurance.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.  
47-25351-01

Docket No.  
030-34021

**Amendment No.**  
**15**


15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application(s) dated:

1. January 2, 2001 [complete renewal application]

B. Letters and/or facsimiles dated:

1. May 9, 2001 [change RSO]
2. **June 5, 2001 [closeout request for MacCorkle Ave address (10CFR30.36 report)]**
3. **July 1, 2001 [closeout survey for MacCorkle address]**



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

DATE August 1, 2001

BY /RA/

DAVID J. COLLINS  
Region II, Division of Nuclear Materials Safety  
61 Forsyth Street, SW, Suite 23T85  
Atlanta, GA 30303-8931